Introduction
============

Venous thromboembolism (VTE), which includes deep-vein thrombosis (DVT) and pulmonary embolism (PE), is a common, life-threatening condition in many cancer outpatient populations. [@JR170171-1] [@JR170171-2] [@JR170171-3] [@JR170171-4] Patients with cancer across most common tumour types are at a four- to sevenfold greater risk for VTE compared with individuals without cancer. [@JR170171-5] [@JR170171-6] The risk of cancer-associated VTE varies during the course of the disease, being especially high in the first few months after diagnosis and surgical management, during systemic cancer treatment and in late-stage metastatic disease. [@JR170171-5] [@JR170171-6] [@JR170171-7] [@JR170171-8] A recent real-world retrospective analysis of a health care claims database that included 27,479 solid tumour patients reported that the rate of VTE at 3.5 months after the initiation of systemic cancer therapy was on average 7.3% (range: 4.6--11.6%) and that the cumulative risk continued to increase to 13.5% (range: 9.8--21.3%) at 12 months. [@JR170171-9] The highest rate of VTE was observed among patients receiving systemic cancer therapy for tumours of the pancreas, stomach or lung. [@JR170171-7] [@JR170171-8] [@JR170171-9] [@JR170171-10]

Development of VTE in patients with cancer is associated with substantial morbidity and mortality, as well as higher health care costs. [@JR170171-11] Venous thromboembolism is the second leading cause of death in ambulatory patients with cancer. [@JR170171-10] Furthermore, patients with cancer who develop VTE have a threefold increase in hospitalizations and length of hospital stay, as well as higher health care costs, compared with cancer patients without VTE ( *p*  \< 0.0001). [@JR170171-11] The occurrence of VTE also complicates the clinical management of cancer and may terminate or delay needed anticancer therapies.

Cancer-associated VTE occurs primarily in the outpatient setting, whereas major public health efforts to institute thromboprophylaxis have focused on the inpatient population. Previous studies of thromboprophylaxis with low-molecular-weight heparins (LMWH) in ambulatory patients with cancer demonstrated that anticoagulation was associated with a significant relative risk reduction in VTE, although the absolute benefit was relatively modest, thereby necessitating prophylactic treatment of a large number of patients to prevent a single VTE event. [@JR170171-12] [@JR170171-13] [@JR170171-14] [@JR170171-15] Because the studies included lower-risk patients and had a relatively short duration (∼3 to 4 months), they may not have been adequate to appropriately assess the value of prophylactic anticoagulation in outpatients with cancer and higher risk of VTE. Consequently, current clinical guidelines do not recommend routine outpatient VTE prophylaxis in most ambulatory patients with cancer (except for multiple myeloma and select high-risk solid tumours), [@JR170171-1] [@JR170171-2] [@JR170171-3] [@JR170171-4] because of the uncertainty regarding the overall benefit-to-risk profile in this unselected patient population.

Although cancer increases the risk for VTE, individual risk factors cannot identify high-risk patients for thromboprophylaxis. The Khorana score, which includes multiple risk factors, was derived and validated in patients initiating chemotherapy in the outpatient setting. Five risk factors were identified that were predictive of chemotherapy-related VTE ( [Table 1](#TB170171-1){ref-type="table"} ). [@JR170171-16] This risk score was subsequently validated in multiple settings and evaluated in more than 12,000 patients [@OR170171-17] [@OR170171-18] [@JR170171-19] [@JR170171-20] [@JR170171-21] [@JR170171-22] ( [Table 2](#TB170171-2){ref-type="table"} ). [@JR170171-23] [@JR170171-24] [@JR170171-25] [@JR170171-26] [@OR170171-27] [@OR170171-28] [@OR170171-29] [@JR170171-30] [@JR170171-31] [@JR170171-32] [@JR170171-33] [@JR170171-34] [@JR170171-35] [@JR170171-36] [@JR170171-37]

###### Modified risk stratification model for cancer-associated VTE in the ambulatory setting (Khorana Thromboembolic Risk Score)

  --------------------------------------------------------------------------------------------------------------------
  Patient characteristic                                                                                       Score
  ------------------------------------------------------------------------------------------------------------ -------
  Cancer\                                                                                                       \
   Very high risk: stomach, pancreas [a](#FN170171-2){ref-type="table-fn"}\                                    2\
   High risk (lung, lymphoma, gynaecologic, bladder, testicular, renal tumours)                                1

  Pre-chemotherapy platelet count ≥ 350,000/μL                                                                 1

  Haemoglobin level \< 10 g/dL or use of red cell growth factors                                               1

  Pre-chemotherapy leukocyte count \> 11,000/μL                                                                1

  Body mass index ≥ 35 kg/m ^2^                                                                                1

  Calculate total score, adding points for each criterion in the model [b](#FN170171-3){ref-type="table-fn"}   
  --------------------------------------------------------------------------------------------------------------------

Abbreviation: VTE, venous thromboembolism.

In the very high-risk category, primary brain tumours were removed because patients with known brain tumours are excluded from study inclusion.

Patients at high risk for VTE had a baseline risk score ≥2.

Source: Adapted from Khorana et al. [@JR170171-16]

###### Summary of clinical evidence highlighting the association between cancer and the risk of venous thromboembolism based on the Khorana score

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient population                                    Patients ( *N* )   Duration   Rate of VTE, %                                             
  ----------------------------------------------------- ------------------ ---------- ------------------------ --------------------------------- ----------------------------------
  Retrospective studies                                                                                                                          

   Solid tumours or malignant lymphoma [@JR170171-23]   112                2 y        5.0                      15.9                              41.4

   Any tumour type [@JR170171-24]                       932                NA         13.0                     17.1                              28.2

   Any advanced tumour type [@JR170171-25]              1,415              2 mo       1.5                      4.8                               12.9

   Any tumour type [@JR170171-26]                       378                113 d      3.0                      11.1                              

   Any tumour type [@OR170171-27]                       150                NA         1.9                      3.9                               9.1

   Any tumour type [@OR170171-28]                       2,782              1 y        NA                       Score \>2:\                       OR: 2.54 (95% CI: 1.29--5.03)
                                                                                                               OR: 1.71 (95% CI: 1.16--2.59)     

   Pancreatic tumours [@OR170171-29]                    108                NA         NA                       14.0                              27.0

   Disseminated germ cell tumours [@JR170171-30]        254                11 y       NA                       NA                                OR: 11.8; *p*  \< 0.001

  Prospective studies                                                                                                                            

   Any tumour type [@JR170171-31]                       819                643 d      1.5 (95% CI: 0.6--3.9)   Score = 1:\                       17.7 (95% CI: 11.0--27.8)
                                                                                                               3.8 (95% CI: 1.9--7.4)\           
                                                                                                               Score = 2:\                       
                                                                                                               9.6 (95% CI: 6.2--14.7)           

   Any tumour type [@JR170171-32]                       1,097              3 mo       NA                       NA                                OR: 3.5 (95% CI: 1--12.3)

   Any tumour type [@JR170171-33]                       35                 3 mo       NA                       NA                                23.0

   Any tumour type [@JR170171-34]                       580                3 mo       4.0                      NA                                Score ≥ 2: 11.0

   Any tumour type [@JR170171-35]                       1,685              2 y                                 Score = 1:\                       HR = 6.47 (95% CI: 2.99--14.00)\
                                                                                                               HR = 3.23 (95% CI: 1.53--6.81)\   *p*  \< 0.001
                                                                                                               *p*  = 0.002;\                    
                                                                                                               Score = 2:\                       
                                                                                                               HR = 4.63 (95% CI: 2.20--9.75)\   
                                                                                                               *p*  \< 0.001                     

  Pooled analysis                                                                                                                                

   Non-Hodgkin\'s lymphoma [@JR170171-36]               1,717              NA         2.2 (95% CI: NA)         4.5 (95% CI: 2.3--6.7)            6.6 (95% CI: 2.4--10.8)\
                                                                                                                                                 *p*  = 0.012
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not applicable; OR, odds ratio; VTE, venous thromboembolism.

Source: Adapted from Angelini et al. [@JR170171-37]

Current American Society of Clinical Oncology clinical practice guidelines and other clinical guidelines recommend this score as the only validated risk assessment tool for the prediction of cancer-associated VTE in outpatients. [@JR170171-3] [@JR170171-4] [@JR170171-38] [@JR170171-39] The data presented in [Table 2](#TB170171-2){ref-type="table"} clearly highlight the high risk of VTE in patients with cancer and underscore the urgent need for novel therapies for primary thromboprophylaxis in this patient population.

Rivaroxaban is a potent, oral, highly selective, direct inhibitor of factor Xa. Previous clinical studies demonstrated that rivaroxaban is effective in VTE prophylaxis in patients undergoing hip/knee replacement surgery (RECORD 1--4) and in the treatment and secondary prevention of VTE in patients with acute symptomatic DVT (EINSTEIN-DVT) or PE (EINSTEIN-PE), with an acceptable safety profile. [@JR170171-40] [@JR170171-41] [@JR170171-42] [@JR170171-43] [@JR170171-44] [@JR170171-45] In a pooled subgroup analysis of EINSTEIN-DVT and EINSTEIN-PE in patients with a cancer (8% of total population), recurrent VTE occurred in 5% of patients treated with rivaroxaban and in 7% of those receiving enoxaparin plus vitamin K antagonist (VKA) therapy (hazard ratio \[HR\]: 0.67; 95% confidence interval \[CI\]: 0.35--1.30). [@JR170171-43] [@JR170171-44] [@JR170171-46] Additionally, clinically relevant bleeding occurred in 14% of patients receiving rivaroxaban and in 16% receiving enoxaparin (HR: 0.80; 95% CI: 0.54--1.20), and major bleeding rates were 2 and 5%, respectively (HR: 0.42; 95% CI: 0.18--0.99). In a recent analysis of a quality improvement initiative to guide rivaroxaban use for cancer-associated thrombosis, the rates of major bleeding and recurrent VTE suggested safety and efficacy to be comparable with past-published experience with LMWH, with the advantage of reduced patient burden. At 6 months, the cumulative incidence of new or recurrent VTE was 4.4% (95% CI: 1.4--7.4%) and major bleeding 2.2% (95% CI: 0--4.2%). [@JR170171-47] These preliminary findings are suggestive that in the prophylactic setting too, anticoagulation with rivaroxaban may reduce the risk for VTE in patients with cancer, with a favourable safety profile.

The CASSINI study has been designed to evaluate the efficacy and safety of rivaroxaban versus placebo for primary thromboprophylaxis in cancer outpatients who are receiving systemic cancer therapy and are at high risk for VTE. High-risk patients will be identified using the Khorana score.

Methods
=======

Study Design and Setting
------------------------

CASSINI (NCT02555878) is a phase 3b, randomized, double-blind, placebo-controlled, parallel-group, multicentre study designed to compare the efficacy and safety of rivaroxaban versus placebo as primary prophylaxis of VTE in ambulatory patients who are receiving systemic cancer treatment and are at an increased risk for VTE. This study consists of three periods: a 2-week screening period; a 180-day, double-blind treatment period; and a 30-day, post-treatment follow-up period ( [Fig. 1](#FI170171-1){ref-type="fig"} ). The duration of study participation for each patient is approximately 32 weeks. CASSINI will enrol approximately 700 patients at 180+ study locations in North America and several countries in Europe. Patients will provide written informed consent before initiation of any study-related procedures, and the study will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory and country-specific requirements. This study will be undertaken at each location only after the independent ethics committee/institutional review board (local/central) has given full approval.

![CASSINI study design. ECOG, Eastern Cooperative Oncology Group.](10-1160-th17-03-0171-i170171-1){#FI170171-1}

Patient Population
------------------

Ambulatory men and women, 18 years of age and older, with various cancer types and a baseline Khorana risk score ≥2, an expected survival of \>6 months, initiating systemic cancer therapy and who are judged by the investigator as appropriate candidates for thromboprophylaxis based on their clinical status, are eligible for study participation. Patients with primary brain tumours or those at risk for bleeding are excluded ( [Table 3](#TB170171-3){ref-type="table"} ).

###### Major inclusion and exclusion criteria for patient selection

  Inclusion criteria                                                                                                                                                                                                           Exclusion criteria
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. ≥18 y of age                                                                                                                                                                                                             1\. Diagnosis of primary brain tumour
  2\. Histologically confirmed solid malignancy including, but not limited to, pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal or lymphoma (haematologic), with locally advanced or metastatic disease   2\. Known history of brain metastases
  3\. ECOG PS 0--2                                                                                                                                                                                                             3\. Haematologic malignancies with the exception of lymphoma
  4\. Khorana score ≥2                                                                                                                                                                                                         4\. Bleeding diathesis, haemorrhagic lesions, active bleeding and other conditions with a high risk for bleeding
  5\. Adequate renal function: CrCl ≥ 30 mL/min                                                                                                                                                                                5\. Life expectancy of ≤6 mo
  6\. Plan to initiate systemic cancer therapy within ± 1 wk of receiving first dose of study drug with the intent of continuing systemic cancer therapy with study drug during the double-blind treatment period              6\. Evidence of VTE on screening CU or incidental VTE identified on spiral CT scans ordered primarily for staging or restaging of malignancy ≤30 d prior to randomization

Abbreviations: CrCl, creatinine clearance; CT, computed tomography; CU, compression ultrasonography; ECOG, Eastern Cooperative Oncology Group; PS, performance status; VTE, venous thromboembolism.

Study Treatment
---------------

Patients will be randomized 1:1 to rivaroxaban 10 mg orally once daily or placebo once daily for 180 (±3) days based on a computer-generated randomization schedule and stratified by tumour type (advanced pancreatic cancer \[APC\] or non-APC); it is estimated that approximately 25% of the patients randomly assigned will be those with APC. Study drug is initiated within ± 1 week of initiation of systemic cancer therapy. Study drug can be taken with or without food and should be taken at the same time each day.

Study drug treatment may be temporarily interrupted or permanently discontinued as necessary for invasive procedures or as medically needed (e.g., bleeding event or required prohibited therapy). It is recommended, when possible, that study drug be discontinued at the discretion of the investigator at least 24 hours before an invasive procedure to minimize the risk of bleeding. Bridging with parenteral anticoagulation may be considered to balance the risk of bleeding against that of VTE. Study drug should be restarted after surgical or other invasive procedures as soon as adequate haemostasis has been established (generally 24 hours for low-risk bleeding or minor surgical procedures and 48 hours for high-risk bleeding or major surgical procedures).

If the platelet count decreases to \<25 × 10 ^9^ /L for more than 1 week, then the patient will be temporarily discontinued until the platelet count returns to ≥25 × 10 ^9^ /L. Patients should have their platelet count monitored carefully if the platelet count decreases to \<50 × 10 ^9^ /L, and investigator discretion should be used. Patients should have their renal function monitored when creatinine clearance (CrCl) drops below \<30 mL/min and investigator discretion should be used with regard to study drug administration. If the patient\'s CrCl decreases to \<15 mL/min, then the patient should be discontinued from study drug treatment.

Study Endpoints
---------------

The primary efficacy composite endpoint is the time from randomization to the first occurrence of objectively confirmed, symptomatic, lower-extremity, proximal DVT; asymptomatic, lower-extremity, proximal DVT; symptomatic, upper-extremity DVT; symptomatic, non-fatal PE; incidental PE; or VTE-related death during the 180-day (±3 days), double-blind treatment period as adjudicated by an independent blinded clinical endpoint committee (CEC; [Table 4](#TB170171-4){ref-type="table"} ). Key secondary efficacy endpoints include symptomatic VTE events (DVT/PE), VTE-related deaths or all-cause mortality. Other secondary efficacy endpoints include time from randomization to the first occurrence of the individual components of the composite primary efficacy endpoint, symptomatic distal DVT, confirmed fatal/non-fatal arterial thromboembolism (ATE) events and confirmed fatal/non-fatal visceral VTE events. In addition, a composite of symptomatic, lower-extremity, proximal DVT; asymptomatic, lower-extremity, proximal DVT; symptomatic, upper-extremity DVT; non-fatal PE; incidental PE; and all-cause mortality will be assessed.

###### CASSINI study endpoints

  Efficacy                                                  
  --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
   Primary                                                  • Composite of time from randomization to first occurrence of symptomatic, lower-extremity, proximal DVT; asymptomatic, lower-extremity, proximal DVT; symptomatic, upper-extremity DVT; symptomatic, nonfatal PE; incidental PE; or VTE-related death during the 180-d (±3 d), double-blind treatment period
   Key secondary                                            • Symptomatic VTE events
  • VTE-related deaths                                      
  • All-cause mortality                                     
   Other                                                    • Time from randomization to first occurrence of individual components of the composite primary efficacy endpoint
                                                            • Confirmed fatal/non-fatal arterial thromboembolism events
                                                            • Confirmed fatal/non-fatal visceral VTE events
                                                            • Composite of symptomatic, lower-extremity, proximal DVT; asymptomatic, lower-extremity, proximal DVT; symptomatic, upper-extremity DVT; symptomatic, non-fatal PE; incidental PE; and all-cause mortality
  Safety                                                    
   Primary                                                  • Time to a major bleeding event as defined by the ISTH
   Secondary                                                • Percentages of clinically relevant non-major bleeding, minor bleeding and any bleeding
  Exploratory                                               
                                                            • Inflammation and hypercoagulability biomarkers (e.g., D-dimer, P-selectin and tissue factor)
  • Pharmacokinetics and exposure response to rivaroxaban   
  • Health care resource utilization                        

Abbreviations: DVT, deep-vein thrombosis; ISTH, International Society on Thrombosis and Haemostasis; PE, pulmonary embolism; VTE, venous thromboembolism.

The primary safety endpoint is the time to a major bleeding event as defined by the International Society on Thrombosis and Haemostasis (ISTH). Bleeding events will be classified using protocol-specified definitions for major, clinically relevant non-major or minor bleeding. Secondary safety endpoints include percentages of clinically relevant non-major bleeding, minor bleeding and any bleeding.

Exploratory endpoints include biomarkers related to inflammation and hypercoagulability (including D-dimer, P-selectin and tissue factor), pharmacokinetics and exposure response to rivaroxaban and health care resource utilization.

Study Procedures
----------------

At the screening visit (day −14 to −1), bilateral, lower-extremity, venous duplex compression ultrasonography (CU) will be performed ( [Table 5](#TB170171-5){ref-type="table"} ). Patients with baseline DVT on screening CU or incidental DVT or PE identified during routine care imaging (e.g., spiral computed tomography \[CT\] scans used primarily for staging or restaging of malignancy) within 30 days prior to randomization will not be eligible for randomization.

###### Schedule of assessments

  Period                                                                                   Screening       Double-blind treatment   Post-treatment (follow-up)                       
  ---------------------------------------------------------------------------------------- --------------- ------------------------ ---------------------------- --------- --------- ---------
  Month                                                                                                    --                       2                            4         6         7
  Day/Week                                                                                 Day −14 to −1   Day 1                    Week 8                       Week 16   Day 180   Day 210
  Eligibility                                                                                                                                                                        
   Obtain informed consent                                                                 X                                                                                         
   Apply inclusion/exclusion criteria                                                      X                                                                                         
   Demographics                                                                            X                                                                                         
   Relevant medical history                                                                X                                                                                         
   Disease staging (using TNM system \[solid tumours\] or Ann Arbor system \[lymphoma\])   X                                                                                         
   Perform physical examination (record height/weight/BMI)                                 X                                                                                         
   Coagulation tests (PT, aPTT and INR)                                                    X                                                                                         
   Record pre-study drugs                                                                  X               X                                                                         
   Record Khorana thromboembolic risk score                                                X                                                                                         
   Randomization                                                                                           X                                                                         
  Study drug administration                                                                                                                                                          
   Contact IWRS for study drug bottle number to dispense                                                   X                        X                            X                   
   Dispense study drug/provide instructions                                                                X                        X                            X                   
   Perform study drug accountability/compliance                                                                                     X                            X         X         
  Safety assessments                                                                                                                                                                 
   Urine pregnancy test                                                                    X                                                                               X         
   Record vital signs including weight                                                     X               X                        X                            X         X         
   Record ECOG performance status                                                          X               X                        X                            X         X         
   Record central venous catheter status                                                   X               X                        X                            X         X         
   Collect laboratory samples (haematology, serum chemistry)                               X                                        X                            X         X         
   Calculated eGFR                                                                         X                                        X                            X         X         
   Clinical events relevant to safety endpoints (bleeding events)                                                                   X                            X         X         X
   Adverse events                                                                          X               X                        X                            X         X         X
   Concomitant therapy                                                                                     X                        X                            X         X         X
   Efficacy assessments                                                                                                                                                              
   Perform bilateral, lower-extremity venous duplex compression ultrasonography            X                                        X                            X         X         
   Clinical events relevant to efficacy endpoints                                                                                   X                            X         X         X
   Telephone follow-up for vital status                                                                                                                                              X
  Exploratory assessments                                                                                                                                                            
   Biomarker sample                                                                        X                                        X                            X         X         
   Pharmacokinetic sample                                                                                                           X                                                

Abbreviations: aPTT, activated partial thromboplastin time; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; INR, international normalised ratio; IWRS, interactive web response system; PT, prothrombin time; TNM, tumour, node, metastasis.

Study visits will occur at week 8 (±7 days), week 16 (±7 days) and day 180/end of treatment (EOT; ±3 days) during the double-blind treatment period. Mandatory CU will be performed at each visit. After a 30-day post-treatment follow-up period, all patients, including those who discontinued study drug before day 180 (±3 days), will be contacted for a day 210 (±7 days)/end-of-study (EOS) follow-up visit. Vital status (i.e., dead, alive or lost to follow-up) as well as clinical status review for suspected outcome and safety bleeding events will be completed. Adverse events (AEs) and concomitant medications will be collected.

Blood samples will be collected at screening, weeks 8 and 16, and day 180/EOT to measure levels of circulating D-dimer, P-selectin and tissue factor.

Study Oversight
---------------

A steering committee has been formed that has overall responsibility for the conduct and reporting of the study. Suspected DVT and non-fatal PE occurring during the double-blind treatment phase and the 30-day follow-up phase will be centrally adjudicated by an independent, blinded CEC. Additionally, incidental DVT or PE, identified from routine care imaging during the same time period, will be adjudicated as asymptomatic DVT or PE events. Finally, any clinical event that suggests the possibility that a major or clinically relevant non-major bleeding event has occurred will be sent for adjudication. An Independent Data Monitoring Committee (IDMC) will ensure that patient safety is not compromised.

Sample Size and Statistical Analyses
------------------------------------

Although estimates of VTE event rates vary, most previous clinical studies, which were generally between 3 and 4 months in duration, reported relative risk reductions between 50 and 64% when ambulatory patients receiving systemic cancer therapy were also treated with anticoagulant therapy. [@JR170171-48] Estimates of assumed VTE events are derived from the Vienna CATS (Cancer and Thrombosis Study) group, which used the Khorana score to monitor 819 ambulatory patients with cancer for symptomatic VTE. [@JR170171-31] The Kaplan--Meier analysis demonstrated that the cumulative probability of VTE after 6 months was 17.7% (95% CI: 11.0--27.8%; *N*  = 93) in patients with a Khorana score ≥3 and 9.6% (95% CI: 6.2--14.7%; *N*  = 221) in patients with a Khorana score of 2. [@JR170171-31] Taken together, these results and those of smaller randomized controlled trials support a projected symptomatic event rate at 180 days of at least 9.5%. Adjudication of asymptomatic proximal DVT and incidental PE is estimated to add 5 to 8%, supporting a 14.5% incidence rate in the placebo group.

Assuming a cumulative incidence rate of 14.5% in the placebo group and 6.0% in the rivaroxaban group for the primary composite endpoint, a total of approximately 700 patients will be required to demonstrate an approximately 60% relative risk reduction in the primary efficacy endpoint with a two-sided, type 1 error rate of 5%, \>90% statistical power and assuming a 20% discontinuation rate.

The CASSINI study will evaluate the hypothesis that prophylaxis with rivaroxaban will be superior to placebo for the composite primary efficacy endpoint. The primary and key secondary efficacy endpoint analyses will be based on the intent-to-treat population, which consists of all randomized patients with valid informed consent. All safety endpoints will be analysed using the safety analysis set, which consists of all randomized patients who receive at least one dose of study drug.

The primary composite endpoint and key secondary efficacy endpoint analyses will be performed on a time-to-first-event basis, using a stratified Cox proportional hazard model and treatment group as a categorical variable. Patients who have no primary efficacy events during the double-blind treatment period, who are lost to follow-up, who die because of non--VTE-related reasons or who withdraw informed consent before the EOT will be censored. To account for competing risks (i.e., deaths from causes other than VTE for efficacy or fatal bleeding for safety), a cumulative incidence approach using Gray\'s two-sample test (two-sided, type 1 error rate of 5%) will be adopted. Associated HR and 95% CI will be calculated using a Fine and Gray regression model. Kaplan--Meier estimates adjusted for competing risk over time will be plotted for time-to-event variables.

Statistical comparison of the primary safety endpoint will be performed using a Cox proportional hazards model with treatment as a covariate. Additionally, the frequency of bleeding events in each treatment group will be summarized. Secondary safety endpoints including AEs and laboratory events will also be summarized.

Discussion
==========

CASSINI will be the first randomized clinical study to compare the efficacy and safety of rivaroxaban, an oral anticoagulant that has undergone rigorous investigation, with placebo in the prevention of VTE in high-risk, ambulatory patients with cancer receiving systemic cancer therapy. At present, no other anticoagulant is approved for primary thromboprophylaxis in outpatients with cancer, and inclusion of a placebo arm will allow a clear determination of the clinical value of rivaroxaban in this setting. Importantly, CASSINI will enrol only patients with cancer who are at increased risk of VTE, as determined by the previously validated Khorana risk score. This approach is consistent with the 2013 and 2014 American Society of Clinical Oncology VTE guidelines, which recommend the use of this risk score rather than individual risk factors to identify patients at increased risk. [@JR170171-3] [@JR170171-38]

Patients with primary brain tumours are excluded from CASSINI because of an increased risk of intracranial bleeding demonstrated in a prior prophylaxis study. The PRODIGE study (NCT00135876) demonstrated that dalteparin LMWH thromboprophylaxis was associated with a higher rate of intracranial bleeding compared with placebo in patients with newly diagnosed malignant glioma (5.1 vs. 1.2% at 12 months). [@JR170171-49] Although this is an area requiring additional investigation, given the known higher rates of bleeding, we believe that this issue is best addressed in a separate, specific study and have chosen to exclude patients with brain tumours from the CASSINI trial.

Supportive evidence from previous studies suggests that rivaroxaban 10 mg daily may be appropriate for effective VTE prevention in high-risk settings. Venous thromboembolism prophylaxis studies in patients undergoing knee or hip replacement surgery demonstrated that rivaroxaban 10 mg daily provides an absolute reduction in VTE risk ranging from 2.6 to 9.2% and has an acceptable safety profile. [@JR170171-40] [@JR170171-41] [@JR170171-42] Data from the EINSTEIN sub-studies provide some experience with the use of rivaroxaban 15 to 20 mg in patients with cancer in the treatment or secondary prophylaxis settings. [@JR170171-43] [@JR170171-44] [@JR170171-46] [@JR170171-50] Clinically relevant bleeding in patients treated with rivaroxaban 15 to 20 mg was similar to the rate reported in the enoxaparin/VKA antagonist group, and there were significantly fewer major bleeding events in the rivaroxaban treatment group. [@JR170171-43] [@JR170171-44] [@JR170171-46] A recent quality assurance initiative to guide rivaroxaban use in cancer-associated thrombosis also suggested efficacy/safety profile to be at least non-inferior to LMWH, with the added benefit of reduced patient burden. [@JR170171-47]

The duration of previous primary VTE prophylaxis studies was generally between 3 and 4 months. However, given the cumulative nature of VTE risk in patients with cancer receiving chemotherapy, [@JR170171-9] the risk of VTE persists beyond this initial time period. The use of a once-daily oral agent allows a patient-friendly approach to extending the period of prophylaxis than has been previously studied. CASSINI was designed to extend the observation window to 6 months after initiation of a new systemic cancer regimen to evaluate whether rivaroxaban can effectively and safely prevent VTE events in patients who typically undergo several cycles of systemic cancer therapy. This approach will allow for a more confident assessment of the benefit--risk profile of rivaroxaban thromboprophylaxis in this population.

Perioperative management of patients who require an elective surgical or other invasive procedure is an area of ongoing uncertainty. There is a lack of data specifically in the high-risk cancer population. Current clinical guidelines from the American Heart Association, the American College of Cardiology, the Heart Rhythm Society and the American College of Chest Physicians recommend that patients at highest risk for thromboembolism without excessive bleeding risk should consider bridging. [@JR170171-51] [@JR170171-52] Thus, bridging anticoagulation may be considered in CASSINI, which is enrolling cancer patients at high risk for VTE, in accordance with these recommendations.

In the CASSINI study, DVT will be diagnosed using CU, the standard method for the diagnosis of this condition because of its low level of invasiveness and high sensitivity. [@JR170171-53] A prospective cohort study of patients undergoing total hip or knee arthroplasty indicated that CU has a positive predictive value (71 vs. 25% for clinical examination) and sensitivity (83 vs. 11% for clinical examination). [@JR170171-54] The Joint American Academy of Family Physicians/American College of Physicians Panel on DVT/PE recommends the use of CU for patients with at least an intermediate probability of lower-extremity DVT. [@JR170171-55]

An important feature of the CASSINI study is the use of screening to detect asymptomatic VTE, which is relatively common and is associated with higher mortality similarly to patients with symptomatic VTE. An analysis of 1,151 radiologic examinations of 135 APC patients demonstrated that incidental events comprised 33.3% of PEs, 21.4% of DVTs and 100% of visceral VTEs. Deep-vein thrombosis (HR: 25; 95% CI: 10--63; *p*  \< 0.0001), PE (HR: 8.9; 95% CI: 2.5--31.7; *p*  = 0.007) and visceral events (HR: 2.6; 95% CI: 1.6--4.2; *p*  = 0.0001) were all independently associated with mortality. There was no significant difference between asymptomatic and symptomatic events in terms of conditional survival at 3 or 6 months after diagnosis. [@JR170171-56] Consistent with the documented correlation between asymptomatic VTE and higher mortality, the U.S. and EU (European Union) regulatory authorities accept the use of asymptomatic VTE as a relevant endpoint in registrational studies.

CASSINI is part of CALLISTO, a new global research programme that will evaluate rivaroxaban across the spectrum of prevention and treatment of cancer-associated VTE. CALLISTO will involve more than 4,000 patients worldwide and will comprise nine initiatives, including several clinical studies, registries, a survey and expert guidance. [@JR170171-57] The CASSINI study will provide the first data related to the use of longer-term, oral anticoagulation for the primary prevention of VTE in high-risk, ambulatory patients with cancer who are receiving systemic cancer therapy. The only other primary VTE prevention study is the phase 2 AVERT study (NCT02048865), which will evaluate the efficacy and safety of the oral anticoagulant apixaban for the prevention of VTE in high-risk ambulatory patients with cancer. Treatment with an effective and well-tolerated oral anticoagulant, administered once daily, has the potential to reduce the burden of VTE and its consequences for patients with cancer.

What is known about this topic?
===============================

-   Patients with cancer are at a four- to sevenfold greater risk for venous thromboembolism (VTE) compared with individuals without cancer. The risk differs among cancer patients, and the Khorana risk score allows for identification of patients with cancer at increased risk for VTE.

-   Cancer-associated VTE occurs primarily in the outpatient setting, and VTE is the second leading cause of death in ambulatory patients with cancer.

-   Previous studies of thromboprophylaxis with LMWH (low-molecular-weight heparins) in ambulatory patients with cancer have demonstrated that anticoagulation is associated with a significant relative risk reduction in VTE, but current clinical guidelines do not recommend routine outpatient VTE prophylaxis because the overall benefit-to-risk profile in an unselected patient population is uncertain. At present, no anticoagulant is approved for primary thromboprophylaxis in outpatients with cancer.

What does this paper add?
=========================

-   The CASSINI trial will be the first randomized clinical study designed to evaluate the efficacy and safety of rivaroxaban, an oral anticoagulant, versus placebo for prevention of VTE in high-risk, ambulatory patients with cancer receiving systemic cancer therapy.

-   It will provide the first data related to the use of longer-term, oral anticoagulation for the primary prevention of VTE in this setting.
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